Skip to main navigation

Investor Relations

Home
Investors & Media
Contact Us
Careers

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Press Releases

Year

Feb 13, 2023

BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium

Feb 08, 2023

BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer

Jan 11, 2023

BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 13 of 13

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Products
Our Pipeline
Our Science
Patients & Advocacy

Home
Investors & Media
Contact Us
Careers

Copyright © 2023 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap